Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies. - Wikidata - awgldk - TriplyDB

Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies.

Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies.

http://www.wikidata.org/entity/Q38451680

about

Perampanel inhibition of AMPA receptor currents in cultured hippocampal neurons Epilepsy, Antiepileptic Drugs, and Aggression: An Evidence-Based Review Perampanel Perampanel for focal epilepsy: insights from early clinical experience Perampanel in the management of partial-onset seizures: a review of safety, efficacy, and patient acceptability Review of clinical studies of perampanel in adolescent patients Clinical efficacy of perampanel for partial-onset and primary generalized tonic-clonic seizures Mechanisms of Action of Antiseizure Drugs and the Ketogenic Diet Efficacy of perampanel: a review of pooled data.Two-year real-world experience with perampanel in patients with refractory focal epilepsy: Austrian data.DRESS associated with perampanel administration in a child with drug-resistant epilepsy.Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: results from phase III extension study 307.The AMPA receptor antagonist perampanel in the adjunctive treatment of partial-onset seizures: clinical trial evidence and experience.Perampanel efficacy and tolerability with enzyme-inducing AEDs in patients with epilepsy.Time to prerandomization monthly seizure count in perampanel trials: A novel epilepsy endpoint Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy A randomized trial.Perampanel efficacy and safety by gender: Subanalysis of phase III randomized clinical studies in subjects with partial seizures Psychiatric and behavioral adverse events in randomized clinical studies of the noncompetitive AMPA receptor antagonist perampanel.2014 Epilepsy Benchmarks Area III: Improve Treatment Options for Controlling Seizures and Epilepsy-Related Conditions Without Side Effects Impact of perampanel on pharmacokinetics of concomitant antiepileptics in patients with partial-onset seizures: pooled analysis of clinical trials.Perampanel (Fycompa): A Review of Clinical Efficacy and Safety in Epilepsy.New developments in the management of partial-onset epilepsy: role of brivaracetam.BGG492 (selurampanel), an AMPA/kainate receptor antagonist drug for epilepsy.Perspective on the use of perampanel and intravenous carbamazepine for generalized seizures.The discovery and development of perampanel for the treatment of epilepsy.Perampanel: A Review in Drug-Resistant Epilepsy.Perampanel in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus.Practical Use of Newer Antiepileptic Drugs as Adjunctive Therapy in Focal Epilepsy.Current role of perampanel in pediatric epilepsy.New antiepileptic drugs: focus on ezogabine, clobazam, and perampanel.Tolerability and Safety of Commonly Used Antiepileptic Drugs in Adolescents and Adults: A Clinician's Overview.Clinical Experience With Perampanel for Refractory Pediatric Epilepsy in One Canadian Center.Effect of adjunctive perampanel on the quality of sleep and daytime somnolence in patients with epilepsy.Sustained seizure remission on perampanel in progressive myoclonic epilepsy (Lafora disease).Perampanel: a selective AMPA antagonist for treating seizures.Add-on perampanel in Lance-Adams syndrome.Perampanel for adjunctive treatment of partial-onset seizures: a pooled dose-response analysis of phase III studies.Seizure control and improvement of neurological dysfunction in Lafora disease with perampanel.Efficacy of perampanel in a patient with epilepsia partialis continua.Adjunctive perampanel in partial-onset seizures: Asia-Pacific, randomized phase III study.

P2860

Q21131943-6784FA02-45EC-4ABC-8F41-A7E871B6EB75 Q26743786-F71A1C32-A73E-48ED-9154-A9BAEF4D4BD4 Q26773308-83B21B36-2673-49A9-B855-9A965E5DA0CA Q26778392-4D40FE54-0B1C-4583-8EEC-E6EA4207AA26 Q26796447-007A077A-7AE2-499A-89F0-27FBECC1E18E Q28077432-8AC9BEC6-393B-442C-85D5-BF7B05F3EB02 Q28078666-C4EA6639-887A-4972-9FCB-559BEF65F4D2 Q28272457-2E075574-1EF6-423E-8575-41B648F6686D Q30728243-18F54023-6426-4CF5-A115-0A1501039E94 Q31140311-4CCB80F9-6BFE-4894-83C4-FF0357F4B8F4 Q34771205-6CC80048-FB27-4471-B485-2471AC37FF58 Q34823061-776AD769-981C-4489-9B55-279CE147CE3E Q35537344-B236FCB7-C5C7-496E-9F4D-FB7863EA06CE Q35611628-F514C31F-C7D3-4085-BB71-7F8C4E80AD99 Q35639962-304656E2-974A-487E-8A75-A0C5AE710E54 Q36052924-D0C42A5C-4266-4C4D-AC19-92ADE6E89185 Q36554228-BCC9C223-E2E8-43BD-B45C-24A2831D6065 Q36592836-E6104CB7-F666-4002-B70C-22A3F2889EE1 Q37021062-4D765993-237A-45E6-9E46-AAEE07FF12DF Q37149455-A6061DF3-AD21-444C-BBD0-A6E844C04E1D Q37372197-D54BDFE8-4586-48B2-A33D-BC220B80A8C1 Q37693757-B443F0AD-4164-4E3F-9C35-125A77CF3328 Q38154633-F4D6C965-7F6B-4600-A230-88819A1C30AD Q38179459-B28F8EBF-B880-4A89-89D0-2F2448F884F4 Q38190084-2D943A35-0B0A-41C8-B4D7-6879DAFDF938 Q38586792-67C60341-3895-4460-A49C-EC12BE50E3E2 Q38599106-0D6EE75D-BA3A-4526-AEB4-93D5D3C1B76B Q38617833-1CCDF2EF-B22B-40E1-9702-42CC82B4D7AB Q38675314-963F09EB-2F32-4A6A-AB98-B366D1819D6B Q38851234-221DF94A-3E83-498C-8C07-B19DFAB2BA79 Q39094490-C81E4D82-69B7-443C-A8C9-1A14ABEE1D8D Q39311787-E18A72E3-C498-4598-A0AA-5A8FC064E0BB Q40345208-964AB0A4-FF97-4C36-9FED-0B5DF0EE3805 Q41455462-815E8447-4833-42E2-811C-6350520E485B Q41873465-D95AFF44-9F11-46C9-A65E-4CD675D5FD69 Q42426744-89F8D74B-C003-4DD8-B53A-E312D012EBB9 Q42647249-26CC4954-5328-4A24-93BC-F614304BA126 Q43120633-EA3B85E5-99D6-4FE9-9363-BF8072F21577 Q47101524-6AC31694-95BE-4556-8283-BF07D3EDA953 Q47293306-EC98D1D1-7B3B-4338-9581-01B5E261557E

P2860

Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies.

http://www.wikidata.org/entity/Q38451680

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Efficacy and safety of adjunct ...... is of three phase III studies.

@en

type

label

Efficacy and safety of adjunct ...... is of three phase III studies.

@en

prefLabel

Efficacy and safety of adjunct ...... is of three phase III studies.

@en

P1433

Q38451680-FAACA119-EA30-4FA4-A5DE-29CEFA984085

P1476

Q38451680-1EBC900E-F052-4240-A8D9-A81011F8D4E0

P2093

Q38451680-112EA2CA-BB44-42FA-94D2-466DDCA8CAC1

Q38451680-32919841-6082-4424-89FA-1E2A1D00D300

Q38451680-781150CD-C41E-40DD-B0CB-5179346C578C

Q38451680-81C21207-94D1-4824-815E-07E1D3D58ABC

Q38451680-9AF4E46D-66D7-4377-91C3-BD595746240A

Q38451680-9E7EBD01-E25D-4AA6-B306-1256CC9AE7F9

Q38451680-F51A6D21-3B6B-48A0-B266-2475D11538C0

Q38451680-FDA593C8-6930-45E1-A92F-896EDDC797EB

P2860

Q38451680-37846E6F-29B6-4246-B7F6-7981A3748D74

Q38451680-403938F1-2896-451E-A848-11627A1425E7

Q38451680-424732EC-E5DA-430B-AC53-DAFA8CE436A0

Q38451680-5E3FC06A-23F0-4A90-8A5D-DE4AF7B00C28

Q38451680-65BF4F8B-055A-4F5D-90FA-134B1351317B

Q38451680-6F864EA1-D788-4CD5-8770-3B732C3FA747

Q38451680-873777B4-8252-4F96-A01B-90D30A1FAF01

Q38451680-8D4F4409-6DB6-4BD9-8EA8-871B19421560

Q38451680-9379A305-D613-4AE5-9F14-E7BDF5E1393B

Q38451680-972002B9-5770-4D68-B2A2-658CF02DECA0

P304

Q38451680-430353F9-FED9-44D5-BDFD-AF60ABE5979E

P31

Q38451680-2D88E4B2-C164-4E18-9E12-8D81B77A7CC1

P356

Q38451680-39F81500-F679-445C-95D5-75ECB15F7101

P433

Q38451680-AEF8CBB1-6CF4-46BC-9B41-1DC8BCCD64C7

P478

Q38451680-8A44B080-1563-4313-8A75-D92C7A9CE0B9

P50

Q38451680-730A5C9B-AE76-4089-9D82-88AC7E1C29F1

Q38451680-CED6AF25-F9D8-4631-95D3-5554A33D4BFA

P577

Q38451680-B51C90C3-B5FD-4470-AFA1-02D851D449C0

P698

Q38451680-44C48643-68AC-4702-97C1-D010F2355D89

P356

P1433

P1476

Efficacy and safety of adjunct ...... sis of three phase III studies

@en

P2093

Andrew Satlin

http://www.w3.org/2001/XMLSchema#string

Antonio Laurenza

http://www.w3.org/2001/XMLSchema#string

Bernhard J Steinhoff

http://www.w3.org/2001/XMLSchema#string

David Squillacote

http://www.w3.org/2001/XMLSchema#string

Elinor Ben-Menachem

http://www.w3.org/2001/XMLSchema#string

Haichen Yang

http://www.w3.org/2001/XMLSchema#string

Jin Zhu

http://www.w3.org/2001/XMLSchema#string

Lynn Kramer

http://www.w3.org/2001/XMLSchema#string

P2860

Revisiting AMPA receptors as an antiepileptic drug target

Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304

Refractory epilepsy: clinical overview.

Antiepileptic drug therapy the story so far.

Perampanel, a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307.

Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy.

Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial.

Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures.

A novel anti-epileptic agent, perampanel, selectively inhibits AMPA receptor-mediated synaptic transmission in the hippocampus.

Seizure-free outcome in randomized add-on trials of the new antiepileptic drugs.

P304

1481-1489

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/EPI.12212

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

54

http://www.w3.org/2001/XMLSchema#string

P50

Philippe Ryvlin

Simon D Shorvon

P577

2013-05-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23663001

http://www.w3.org/2001/XMLSchema#string